FABP4 and neoplasm: To determine if PPARγ is also involved in FABP4 overexpression in tumor cells exposed to adipocyte-derived factors, we treated tumor cells with either PPARγ agonist rosiglitazone (ROSI) or with Adipo CM in the absence or presence of PPARγ antagonist GW9662.